ArticleInnovation (Cambridge (Mass.))2021
A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease.
Article in Innovation (Cambridge (Mass.)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Nanomaterials for Alzheimer's disease: emerging strategies in diagnosis and therapy.Journal of nanobiotechnology · 2026Review
- A Mini-review on Unlocking Cognitive Enhancement: An Innovative Strategy for Optimal Brain Functions.Central nervous system agents in medicinal chemistry · 2026Review
- Biomedical Applications of Nanozymes: An Enzymology Perspective.Angewandte Chemie (International ed. in English) · 2025Review
- Combating multiple aetiologies of Alzheimer's disease to rescue behavioural deficits.Chemical science · 2025Article
- A polymerized probucol nanoformulation with neutrophil extracellular vesicle camouflage for cerebral ischemia-reperfusion injury therapy.Innovation (Cambridge (Mass.)) · 2025Article
- Interface potential-induced natural antioxidant mimic system for the treatment of Alzheimer's disease.Communications chemistry · 2024Article
- Targeted nucleic acid delivery for traumatic brain injury: Overcoming blood-brain barrier challenges.Molecular therapy. Nucleic acids · 2024Article
- Uncovering the Fate and Risks of Intravenously Injected Prussian Blue Nanoparticles in mice by an Integrated Methodology of Toxicology, Pharmacokinetics, Proteomics, and Metabolomics.Particle and fibre toxicology · 2023Article
- Perioperative platelet count in peripheral blood is associated with the early stage of PND after major orthopedic surgery: a prospective observational study.BMC geriatrics · 2022Observational
- Impact of Albumin Pre-Coating on Gold Nanoparticles Uptake at Single-Cell Level.Nanomaterials (Basel, Switzerland) · 2022Article
- Impaired dynamic cerebral autoregulation is associated with the severity of neuroimaging features of cerebral small vessel disease.CNS neuroscience & therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antioxidation and adjustable treatment strategies are critical for the effective treatment of Alzheimer's disease (AD). Here, we design a dual-targeted Prussian blue nanoformulation (PTCN) that can cross the blood-brain barrier and target amyloid beta aggregates further exert antioxidant effects. An adjustable gradient dosing strategy with PTCN is used for the first time to design the preventive and therapeutic trials based on the severity of oxidative stress at different AD stages. The results show that PTCN could effectively ameliorate AD-related pathological processes, improve the cognitive decline, and rescue hippocampal atrophy of APP/PS1 mice in both preventive and therapeutic trials. Altogether, PTCN provided here is a successful combination of three traditional biomaterials with good biosafety, which has broad prospects for the early prevention, mild remission, and late treatment of AD, and is expected to be developed into personalized therapeutic drugs and healthcare products for clinical AD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.